Page last updated: 2024-12-05

phenylmethylsulfonyl fluoride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phenylmethylsulfonyl Fluoride: An enzyme inhibitor that inactivates IRC-50 arvin, subtilisin, and the fatty acid synthetase complex. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

phenylmethanesulfonyl fluoride : An acyl fluoride with phenylmethanesulfonyl as the acyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4784
CHEMBL ID190503
CHEBI ID8102
SCHEMBL ID24938
MeSH IDM0016570

Synonyms (71)

Synonym
nsc88499
benzylsulfonyl fluoride
nsc-88499
phenylmethanesulfonyl fluroide
wln: wsf1r
.alpha.-toluenesulfonyl fluoride
EN300-24380
alpha-toluenesulfonyl fluoride
alpha-toluenesulphonyl fluoride
CHEBI:8102 ,
NCI60_041962
NCIOPEN2_001527
HSCI1_000354
benzenemethanesulfonyl fluoride
C06747
329-98-6
pmsf
phenylmethanesulfonyl fluoride
phenylmethylsulfonyl fluoride
phenylmethanesulfonyl fluoride, >=98.5% (gc)
einecs 206-350-2
nsc 88499
benzylsulphonyl fluoride
brn 2088311
phenylmethylsulfonylfluoride
P-4170
phenylmethanesulfonyl fluoride, >=99.0% (t)
B3473
B1062
inchi=1/c7h7fo2s/c8-11(9,10)6-7-4-2-1-3-5-7/h1-5h,6h2
ybyrmvivwmbxkq-uhfffaoysa-
phenylmethylsulfonyl-fluoride
CHEMBL190503 ,
BMSE000752
bdbm50171289
AKOS001270830
phenylmethylsulphonyl fluoride
unii-57kd15003i
3-11-00-00331 (beilstein handbook reference)
57kd15003i ,
a-toluenesulfonyl fluoride
A821558
phenylmethanesulphonyl fluoride
FT-0631967
NCGC00346705-01
.alpha.-toluenesulphonyl fluoride
pmsf [mi]
S3025
BRD-K33422401-001-01-5
CCG-208035
CCG-207862
HY-B0496
SCHEMBL24938
DTXSID6059819
phenylmethane-sulphonyl fluoride
phenyl methane sulfonylfluoride
AB01566861_01
mfcd00007424
HMS3656J16
pmsf, phenylmethylsulfonyl fluoride
SW219534-1
Q411575
SY038235
Z190630174
pmsf (phenylmethylsulfonyl fluoride)
PS-10935
PMF ,
HMS3885O03
AMY27009
pms-f;pmsf
phenylmethanesulfonylfluoride

Research Excerpts

Overview

Phenylmethylsulfonyl fluoride (PMSF) is an inhibitor of the enzyme (an amidase) which hydrolyzes anandamide to arachidonic acid and ethanolamine. It was shown to be a very effective irreversible inhibitor, completely inactivating the penicillin acylase from A.

ExcerptReferenceRelevance
"Phenylmethylsulfonyl fluoride (PMSF) is a protease and esterase inhibitor that causes protection, or potentiation/"promotion," of organophosphorus delayed neuropathy (OPIDN), depending on whether it is dosed before or after an inducer of delayed neuropathy, such as mipafox. "( Kinetic interactions of a neuropathy potentiator (phenylmethylsulfonyl fluoride) with the neuropathy target esterase and other membrane bound esterases.
Estévez, J; Mangas, I; Vilanova, E, 2014
)
2.1
"Phenylmethylsulfonyl fluoride (PMSF) is a protease and esterase inhibitor that causes protection or potentiation/promotion of organophosphorus delayed neuropathy (OPIDN) depending on whether it is dosed before or after an inducer of delayed neuropathy. "( Phenylmethylsulfonyl fluoride, a potentiator of neuropathy, alters the interaction of organophosphorus compounds with soluble brain esterases.
Estévez, J; Mangas, I; Vilanova, E, 2012
)
3.26
"Phenylmethylsulfonyl fluoride (PMSF) is an inhibitor of the enzyme (an amidase) which hydrolyzes anandamide to arachidonic acid and ethanolamine."( Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor.
Arreaza, G; Deutsch, DG; Hill, WA; Lin, S; Makriyannis, A; Morse, KL; Omeir, RL; Salehani, D, 1997
)
1.02
"Phenylmethylsulfonyl fluoride was shown to be a very effective irreversible inhibitor, completely inactivating the penicillin acylase from A."( Kinetic study of penicillin acylase from Alcaligenes faecalis.
Guranda, D; Sheldon, R; Svedas, V; van Langen, L; van Rantwijk, F, 1997
)
1.02

Effects

Phenylmethylsulfonyl fluoride (PMSF) has been shown to inhibit the addition of ethanolamine phosphate to glycosylphosphatidylinositol (GPI) intermediates. It has no effect on the rise in intracellular calcium or the depolarization induced by fMet-Leu-Phe but does decrease the extent of repolarization and abolishes hyperpolarization.

ExcerptReferenceRelevance
"Phenylmethylsulfonyl fluoride (PMSF) has been shown to inhibit the addition of ethanolamine phosphate to glycosylphosphatidylinositol (GPI) intermediates in Trypanosoma brucei (Masterson, W. "( The effects of phenylmethylsulfonyl fluoride on inositol-acylation and fatty acid remodeling in African trypanosomes.
Ferguson, MA; Güther, ML; Masterson, WJ, 1994
)
2.08
"Phenylmethylsulfonyl fluoride has no effect on the rise in intracellular calcium or the depolarization induced by fMet-Leu-Phe but does decrease the extent of repolarization and abolishes hyperpolarization."( Actions of the protease inhibitor phenylmethylsulfonyl fluoride on neutrophil granule enzyme secretion and superoxide production induced by fMet-Leu-Phe and phorbol 12-myristate-13-acetate.
Becker, EL; Gomez-Cambronero, J; Mege, JL; Molski, TF; Naccache, PH; Sha'afi, RI, 1989
)
1.28

Treatment

ExcerptReferenceRelevance
"Pretreatment with phenylmethylsulfonyl fluoride (PMSF) 24 h before TOCP administration prevented OPIDN and restored the TOCP-induced changes of phospholipids except GPC."( Disturbed phospholipid homeostasis in endoplasmic reticulum initiates tri-o-cresyl phosphate-induced delayed neurotoxicity.
Sun, YJ; Wang, P; Wu, YJ; Xu, MY; Zhu, L, 2016
)
0.76

Toxicity

ExcerptReferenceRelevance
" Prior administration of phenylmethylsulfonyl fluoride (PMSF) reduced the incidence of damage to the peripheral nerve of animals dosed with TPP, but did not prevent toxic effects on the cell bodies in the spinal cord or the clinical effects."( Histopathological assessment of triphenyl phosphite neurotoxicity in the hen.
Abou-Donia, MB; Brown, HR; Carrington, CD, 1988
)
0.58
"Isoline, a major retronecine-type pyrrolizidine alkaloid (PA) from the Chinese medicinal herb Ligularia duciformis, was suggested to be the most toxic known PA."( In vitro metabolism of isoline, a pyrrolizidine alkaloid from Ligularia duciformis, by rodent liver microsomal esterase and enhanced hepatotoxicity by esterase inhibitors.
Akao, T; Hattori, M; Nakamura, N; Sasahara, M; Takagawa, K; Tang, J; Wang, ZT, 2007
)
0.34

Pharmacokinetics

ExcerptReferenceRelevance
" Approximately 50% of the radioactivity was removed from the circulation 8 min after the injection, and the half-life of inactive 125I-PMSF-kallikrein was markedly prolonged by bilateral nephrectomy."( Clearance and metabolism of glandular kallikrein in the rat.
Carretero, OA; Maitra, SR; Rabito, SF; Seto, M, 1985
)
0.27

Compound-Compound Interactions

ExcerptReferenceRelevance
" Additionally, we established the relationship between treatment with ACEA in combination with LEV and hippocampal neurogenesis in mouse brain."( Levetiracetam combined with ACEA, highly selective cannabinoid CB1 receptor agonist changes neurogenesis in mouse brain.
Andres-Mach, M; Haratym-Maj, A; Maj, M; Rola, R; Szewczyk, A; Zagaja, M; Łuszczki, JJ, 2019
)
0.51

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Phenylmethylsulfonyl fluoride (PMSF) is a protease and esterase inhibitor. It causes protection or potentiation/promotion of organophosphorus delayed neuropathy (OPIDN) Depending on whether it is dosed before or after an inducer of delayed Neuropathy.

ExcerptRelevanceReference
" PFK activity decreased in sciatic nerve 15 days after dosing with TOCP or TOCP + PMSF."( Decrease of phosphofructokinase activity in relation to the pathogenesis of triorthocresyl-phosphate-induced delayed neuropathy.
Hernández, AF; Pla, A; Villanueva, E, 1992
)
0.28
" The activity is optimally assayed at 25 degrees C, has a sigmoidal dose-response curve, and is heat-sensitive (56 degrees C)."( Complement-like activity in the sea star, Asterias forbesi.
Leonard, LA; Strandberg, JD; Winkelstein, JA, 1990
)
0.28
"The induction of central-peripheral distal axonopathy in hens singly dosed with some organophosphorus (OP) compounds, such as di-n-butyl-2,2-dichlorovinyl phosphate (DBDCVP), requires greater than 80% organophosphorylation and subsequent intramolecular rearrangement ("aging") of a protein [neuropathy target esterase (NTE)] in the axon."( Progressive deficit of retrograde axonal transport is associated with the pathogenesis of di-n-butyl dichlorvos axonopathy.
Lotti, M; Moretto, A; Sabri, MI; Spencer, PS, 1987
)
0.27
" Prior administration of phenylmethylsulfonyl fluoride (PMSF) reduced the incidence of damage to the peripheral nerve of animals dosed with TPP, but did not prevent toxic effects on the cell bodies in the spinal cord or the clinical effects."( Histopathological assessment of triphenyl phosphite neurotoxicity in the hen.
Abou-Donia, MB; Brown, HR; Carrington, CD, 1988
)
0.58
" Conversely, another group of rats, pretreated with Mipafox, was dosed with PMSF when NTE inhibition was 90."( Phenylmethylsulfonyl fluoride protects rats from Mipafox-induced delayed neuropathy.
Padilla, S; Veronesi, B, 1985
)
1.71
" However, PMSF was ineffective at preventing paralysis when given 24 h following dosing with TOCP or when given later than 4 h before DFP administration."( The time course of protection from delayed neurotoxicity induced by tri-o-cresyl phosphate and O,O-diisopropyl phosphorofluoridate by phenyl methyl sulfonyl fluoride in chickens.
Abou-Donia, MB; Carrington, CD, 1983
)
0.27
" This is compatible with the fact that inhibited NTE is autopsy material from hens dosed with PPP can always be reactivated in vitro, presumably because no 'aging' reaction has occurred."( Prophylaxis against and promotion of organophosphate-induced delayed neuropathy by phenyl di-n-pentylphosphinate.
Johnson, MK; Read, DJ, 1993
)
0.29
" However, if PMSF is dosed after a low non-neuropathic dose of a neuropathic OP, its neurotoxicity is 'promoted', causing severe neuropathy."( Discrimination of carboxylesterases of chicken neural tissue by inhibition with a neuropathic, non-neuropathic organophosphorus compounds and neuropathy promoter.
Barril, J; Céspedes, MV; Escudero, MA; Sogorb, MA; Vicedo, JL; Vilanova, E, 1997
)
0.3
" Experiments were aimed to ascertain if neuropathy is caused by repeated dosing with a promoter not causing NTE inhibition and in the absence of deliberate injury to axons."( Repeated low doses of O-(2-chloro-2,3,3 trifluorocyclobutyl) O-ethyl S-propyl phosphorothioate (KBR-2822) do not cause neuropathy in hens.
Jokanovic, M; Lotti, M; Moretto, A, 1998
)
0.3
" When dosed subcutaneously, the tissue concentration of dipterex was high in the brain, spinal cord and muscle at 3 hr after dosing and then concentrated in the spinal cord and muscle for the subsequent 3 hr."( Pharmacokinetics and neurotoxicity of dipterex in hens. A comparative study of administration methods.
Piao, FY; Tian, Y; Xie, X; Yamauchi, T, 1998
)
0.3
"coli was induced at a low dosage of IPTG (0."( Establishment of a simple assay in vitro for hepatitis C virus NS3 serine protease based on recombinant substrate and single-chain protease.
Du, GX; Guan, RB; Hou, LH; Tong, YG; Wang, HT, 2002
)
0.31
" In addition, batch culture in vitro incubations in buffered ruminal fluid were conducted to compare the enzyme product with purified protease sources, and dose-response studies (0 to 10 microL/g of forage DM) were carried out using alfalfa hay as a substrate."( A protease additive increases fermentation of alfalfa diets by mixed ruminal microorganisms in vitro.
Beauchemin, KA; Colombatto, D, 2009
)
0.35
" The hens were pretreated 24h earlier with PMSF and subsequently treated with a single dosage of 750 mg/kg TOCP, then sacrificed on the corresponding time points of 0, 1, 5, 10, and 21 days after dosing TOCP, respectively."( Phenylmethylsulfonyl fluoride protects against the degradation of neurofilaments in tri-ortho-cresyl phosphate (TOCP) induced delayed neuropathy.
Dou, D; Song, F; Xie, K; Yan, Y; Zhang, C; Zhao, X, 2009
)
1.8
" Birds in PMSF + TOCP set were pretreated with PMSF, 24 hours later, hens in both TOCP group and PMSF + TOCP group were administrated with TOCP at a single dosage of 750 mg/kg."( [Effect of phenylmethylsulfonyl fluoride pretreated on neurofilament subunits in spinal cords of hens administrated with tri-o-cresyl phosphate].
Dou, DD; Song, FY; Xie, KQ; Xin, X; Zeng, T; Zhang, CL; Zhao, S; Zhao, XL, 2010
)
0.75
" Adult hens were treated with a dose of 750mg/kg TOCP by gavage, or injected subcutaneously with 60mg/kg phenylmethanesulfonyl fluoride (PMSF) dissolved in DMSO 24h earlier and subsequently treated with TOCP, then sacrificed on the time-points of 0, 1, 5, 10, and 21 days after dosing of TOCP respectively."( Changes in beclin-1 and micro-calpain expression in tri-ortho-cresyl phosphate-induced delayed neuropathy.
Han, X; Song, F; Xie, K; Zeng, T; Zhang, C; Zou, C, 2012
)
0.38
"Phenylmethylsulfonyl fluoride (PMSF) is a protease and esterase inhibitor that causes protection or potentiation/promotion of organophosphorus delayed neuropathy (OPIDN) depending on whether it is dosed before or after an inducer of delayed neuropathy."( Phenylmethylsulfonyl fluoride, a potentiator of neuropathy, alters the interaction of organophosphorus compounds with soluble brain esterases.
Estévez, J; Mangas, I; Vilanova, E, 2012
)
3.26
" This kind of interaction among esterase inhibitors should be considered to study the potentiation/promotion phenomenon, which is observed when some esterase inhibitors enhance the severity of the OP induced neuropathy if they are dosed after a non neuropathic low dose of a neuropathy inducer."( Interactions of neuropathy inducers and potentiators/promoters with soluble esterases.
Estévez, J; Mangas, I; Sogorb, MÁ; Vilanova, E, 2013
)
0.39
"Phenylmethylsulfonyl fluoride (PMSF) is a protease and esterase inhibitor that causes protection, or potentiation/"promotion," of organophosphorus delayed neuropathy (OPIDN), depending on whether it is dosed before or after an inducer of delayed neuropathy, such as mipafox."( Kinetic interactions of a neuropathy potentiator (phenylmethylsulfonyl fluoride) with the neuropathy target esterase and other membrane bound esterases.
Estévez, J; Mangas, I; Vilanova, E, 2014
)
2.1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
serine proteinase inhibitorAn exogenous or endogenous compound which inhibits serine endopeptidases.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
acyl fluorideA compound consisting of an acyl group bonded to fluorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

PathwayProteinsCompounds
sinapate ester biosynthesis221
galloylated catechin biosynthesis013
polyvinyl alcohol degradation29
curcumin degradation117
hemoglobin degradation107
fructose degradation18

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
EWS/FLI fusion proteinHomo sapiens (human)Potency2.23270.001310.157742.8575AID1259252; AID1259255; AID1259256
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty-acid amide hydrolase 1Homo sapiens (human)IC50 (µMol)13.00000.00020.59827.0000AID241871
Neutrophil elastaseHomo sapiens (human)IC50 (µMol)73.69050.00632.073422.3780AID490653; AID490654
MyeloblastinHomo sapiens (human)IC50 (µMol)19.23000.34000.34000.3400AID1170278
Fatty-acid amide hydrolase 1Rattus norvegicus (Norway rat)IC50 (µMol)0.83300.00051.33138.0000AID703163
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (38)

Processvia Protein(s)Taxonomy
fatty acid catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
arachidonic acid metabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
positive regulation of vasoconstrictionFatty-acid amide hydrolase 1Homo sapiens (human)
monoacylglycerol catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
proteolysisNeutrophil elastaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINeutrophil elastaseHomo sapiens (human)
response to yeastNeutrophil elastaseHomo sapiens (human)
leukocyte migration involved in inflammatory responseNeutrophil elastaseHomo sapiens (human)
biosynthetic process of antibacterial peptides active against Gram-negative bacteriaNeutrophil elastaseHomo sapiens (human)
proteolysisNeutrophil elastaseHomo sapiens (human)
intracellular calcium ion homeostasisNeutrophil elastaseHomo sapiens (human)
response to UVNeutrophil elastaseHomo sapiens (human)
extracellular matrix disassemblyNeutrophil elastaseHomo sapiens (human)
protein catabolic processNeutrophil elastaseHomo sapiens (human)
response to lipopolysaccharideNeutrophil elastaseHomo sapiens (human)
negative regulation of chemokine productionNeutrophil elastaseHomo sapiens (human)
negative regulation of interleukin-8 productionNeutrophil elastaseHomo sapiens (human)
positive regulation of interleukin-8 productionNeutrophil elastaseHomo sapiens (human)
defense response to bacteriumNeutrophil elastaseHomo sapiens (human)
positive regulation of MAP kinase activityNeutrophil elastaseHomo sapiens (human)
positive regulation of smooth muscle cell proliferationNeutrophil elastaseHomo sapiens (human)
negative regulation of inflammatory responseNeutrophil elastaseHomo sapiens (human)
positive regulation of immune responseNeutrophil elastaseHomo sapiens (human)
negative regulation of chemotaxisNeutrophil elastaseHomo sapiens (human)
pyroptosisNeutrophil elastaseHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumNeutrophil elastaseHomo sapiens (human)
neutrophil-mediated killing of fungusNeutrophil elastaseHomo sapiens (human)
positive regulation of leukocyte tethering or rollingNeutrophil elastaseHomo sapiens (human)
phagocytosisNeutrophil elastaseHomo sapiens (human)
acute inflammatory response to antigenic stimulusNeutrophil elastaseHomo sapiens (human)
proteolysisMyeloblastinHomo sapiens (human)
membrane protein ectodomain proteolysisMyeloblastinHomo sapiens (human)
positive regulation of cell population proliferationMyeloblastinHomo sapiens (human)
antimicrobial humoral responseMyeloblastinHomo sapiens (human)
collagen catabolic processMyeloblastinHomo sapiens (human)
positive regulation of GTPase activityMyeloblastinHomo sapiens (human)
cell-cell junction maintenanceMyeloblastinHomo sapiens (human)
negative regulation of phagocytosisMyeloblastinHomo sapiens (human)
neutrophil extravasationMyeloblastinHomo sapiens (human)
mature conventional dendritic cell differentiationMyeloblastinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
phospholipid bindingFatty-acid amide hydrolase 1Homo sapiens (human)
fatty acid amide hydrolase activityFatty-acid amide hydrolase 1Homo sapiens (human)
identical protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
acylglycerol lipase activityFatty-acid amide hydrolase 1Homo sapiens (human)
amidase activityFatty-acid amide hydrolase 1Homo sapiens (human)
protease bindingNeutrophil elastaseHomo sapiens (human)
transcription corepressor activityNeutrophil elastaseHomo sapiens (human)
endopeptidase activityNeutrophil elastaseHomo sapiens (human)
serine-type endopeptidase activityNeutrophil elastaseHomo sapiens (human)
protein bindingNeutrophil elastaseHomo sapiens (human)
heparin bindingNeutrophil elastaseHomo sapiens (human)
peptidase activityNeutrophil elastaseHomo sapiens (human)
cytokine bindingNeutrophil elastaseHomo sapiens (human)
serine-type endopeptidase activityMyeloblastinHomo sapiens (human)
signaling receptor bindingMyeloblastinHomo sapiens (human)
protein bindingMyeloblastinHomo sapiens (human)
serine-type peptidase activityMyeloblastinHomo sapiens (human)
enzyme bindingMyeloblastinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneFatty-acid amide hydrolase 1Homo sapiens (human)
cytoskeletonFatty-acid amide hydrolase 1Homo sapiens (human)
organelle membraneFatty-acid amide hydrolase 1Homo sapiens (human)
extracellular regionNeutrophil elastaseHomo sapiens (human)
extracellular spaceNeutrophil elastaseHomo sapiens (human)
cytoplasmNeutrophil elastaseHomo sapiens (human)
cytosolNeutrophil elastaseHomo sapiens (human)
cell surfaceNeutrophil elastaseHomo sapiens (human)
secretory granuleNeutrophil elastaseHomo sapiens (human)
azurophil granule lumenNeutrophil elastaseHomo sapiens (human)
specific granule lumenNeutrophil elastaseHomo sapiens (human)
phagocytic vesicleNeutrophil elastaseHomo sapiens (human)
collagen-containing extracellular matrixNeutrophil elastaseHomo sapiens (human)
extracellular exosomeNeutrophil elastaseHomo sapiens (human)
transcription repressor complexNeutrophil elastaseHomo sapiens (human)
extracellular spaceNeutrophil elastaseHomo sapiens (human)
plasma membraneMyeloblastinHomo sapiens (human)
collagen-containing extracellular matrixMyeloblastinHomo sapiens (human)
extracellular regionMyeloblastinHomo sapiens (human)
extracellular spaceMyeloblastinHomo sapiens (human)
cytosolMyeloblastinHomo sapiens (human)
plasma membraneMyeloblastinHomo sapiens (human)
azurophil granule lumenMyeloblastinHomo sapiens (human)
intracellular membrane-bounded organelleMyeloblastinHomo sapiens (human)
plasma membrane raftMyeloblastinHomo sapiens (human)
extracellular exosomeMyeloblastinHomo sapiens (human)
extracellular spaceMyeloblastinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (75)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID703163Inhibition of rat histidine tagged FAAH expressed in Escherichia coli by coumarin ester substrate fluorescence assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Assay and inhibition of diacylglycerol lipase activity.
AID480913Inhibition of serine protease in excreted-secreted products fraction of Toxoplasma gondii RH tachyzoites infected in african green monkey Vero cells by SDS-PAGE and zymography2010Journal of natural products, May-28, Volume: 73, Issue:5
Action of a pentacyclic triterpenoid, maslinic acid, against Toxoplasma gondii.
AID480907Antimicrobial activity against Toxoplasma gondii RH tachyzoites assessed as inhibition of parasite invasion of african green monkey Vero cells pretreated for 1 hr before cell infection measured 24 to 48 hrs post infection2010Journal of natural products, May-28, Volume: 73, Issue:5
Action of a pentacyclic triterpenoid, maslinic acid, against Toxoplasma gondii.
AID593217Inhibition of FMLP/CB-stimulated superoxide anion generation in human neutrophils treated for 5 mins before FMLP and CB challenge for 10 mins and 3 mins respectively by spectrophotometer analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
Inhibitory effects of Mannich bases of heterocyclic chalcones on NO production by activated RAW 264.7 macrophages and superoxide anion generation and elastase release by activated human neutrophils.
AID381606Inhibition of human C3bBb convertase assessed as C3 cleavage at 1 mM after 30 mins by 12% gel analysis2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Profiling the enzymatic properties and inhibition of human complement factor B.
AID593487Inhibition of chymotrypsin assessed as p-nitroaniline release measured for 15 mins using Bz-L-Tyr-pNA as a substrate by Dixon plot analysis2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Synthesis and biological evaluation of novel irreversible serine protease inhibitors using amino acid based sulfonyl fluorides as an electrophilic trap.
AID703171Inhibition of human DAGLalpha expressed in HEK293T cell membrane using [14C]SAG substrate at 10 uM using JZL184 pretreated protein in detergent free solution by FRET assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Assay and inhibition of diacylglycerol lipase activity.
AID1170278Inhibition of human PR3 using D-DY-FRET as substrate after 30 mins by HPLC analysis2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Reversible ketomethylene-based inhibitors of human neutrophil proteinase 3.
AID595748Inhibition of fMLP/CB-activated human neutrophil degranulation assessed as inhibition of elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate after 5 mins2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Bioactive constituents from the roots of Panax japonicus var. major and development of a LC-MS/MS method for distinguishing between natural and artifactual compounds.
AID1170274Inhibition of human PR3 using N-EY-FRET as substrate at 6 uM after 20 mins by fluorescence assay2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Reversible ketomethylene-based inhibitors of human neutrophil proteinase 3.
AID490653Inhibition of human neutrophil elastase after 30 mins by ELISA2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and evaluation of benzoxazinone derivatives on activity of human neutrophil elastase and on hemorrhagic shock-induced lung injury in rats.
AID319549Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced elastase release at 10 ug/mL2008Journal of natural products, Jan, Volume: 71, Issue:1
Benzoic acid derivatives, acetophenones, and anti-inflammatory constituents from Melicope semecarpifolia.
AID390888Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/Cytochalasin B-induced elastase release2008Journal of natural products, Oct, Volume: 71, Issue:10
Phthalides from Pittosporum illicioides var. illicioides with inhibitory activity on superoxide generation and elastase release by neutrophils.
AID1170275Inhibition of human NE using MeOSuc-AAPV-AMC as substrate at 6 uM after 30 mins by fluorescence assay2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Reversible ketomethylene-based inhibitors of human neutrophil proteinase 3.
AID459779Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/cytochalasin B-induced elastase release2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Antitumor agents. 271: total synthesis and evaluation of brazilein and analogs as anti-inflammatory and cytotoxic agents.
AID490654Inhibition of human leukocyte elastase after 2 mins by ELISA2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and evaluation of benzoxazinone derivatives on activity of human neutrophil elastase and on hemorrhagic shock-induced lung injury in rats.
AID305971Antiinflammatory activity in neutrophil assessed as inhibition of fMLP induced elastase release2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
The evaluation and structure-activity relationships of 2-benzoylaminobenzoic esters and their analogues as anti-inflammatory and anti-platelet aggregation agents.
AID662815Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release using MeO-Suc-Ala-Ala-Pro-Val-MC as substrate by spectrophotometry2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Design and synthesis of gambogic acid analogs as potent cytotoxic and anti-inflammatory agents.
AID1423187Binding affinity to serine residue of human CE1 assessed as adduct formation at 10 uM by mass spectrum analysis2018Journal of natural products, 11-26, Volume: 81, Issue:11
Potent, Irreversible Inhibition of Human Carboxylesterases by Tanshinone Anhydrides Isolated from Salvia miltiorrhiza ("Danshen").
AID703150Inhibition of porcine pancreatic lipase type 2 at 10 uM by FRET assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Assay and inhibition of diacylglycerol lipase activity.
AID703152Inhibition of bacterial lipoprotein lipase at 10 uM by FRET assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Assay and inhibition of diacylglycerol lipase activity.
AID703165Inhibition of rat histidine tagged FAAH expressed in Escherichia coli at 10 uM by coumarin ester substrate fluorescence assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Assay and inhibition of diacylglycerol lipase activity.
AID595746Inhibition of fMLP/CB-stimulated superoxide anion generation in human neutrophils2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Bioactive constituents from the roots of Panax japonicus var. major and development of a LC-MS/MS method for distinguishing between natural and artifactual compounds.
AID490651Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP-induced superoxide anion generation treated 5 mins before FMLP challenge measured after 10 mins by spectrophotometer analysis2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and evaluation of benzoxazinone derivatives on activity of human neutrophil elastase and on hemorrhagic shock-induced lung injury in rats.
AID426988Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/Cytochalasin B-induced elastase release2009Journal of natural products, Jul, Volume: 72, Issue:7
Anti-inflammatory flavonoids from the rhizomes of Helminthostachys zeylanica.
AID241871Irreversible inhibition of fatty acid amide hydrolase2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
AID490652Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP-induced neutrophil elastase release treated 5 mins before FMLP challenge measured after 10 mins2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and evaluation of benzoxazinone derivatives on activity of human neutrophil elastase and on hemorrhagic shock-induced lung injury in rats.
AID346661Half life in mouse brain2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors.
AID381605Inhibition of human C3bBb convertase assessed as C3 cleavage at 1 mM after 30 mins by 7% gel analysis2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Profiling the enzymatic properties and inhibition of human complement factor B.
AID703162Inhibition of human N-terminal histidine tagged full length MAGL expressed in Escherichia coli at 10 uM by by coumarin ester substrate fluorescence assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Assay and inhibition of diacylglycerol lipase activity.
AID663216Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release incubated for 5 mins prior to FMLP/CB-challenge by spectrophotometry2012Journal of natural products, Apr-27, Volume: 75, Issue:4
Indiosides G-K: steroidal glycosides with cytotoxic and anti-inflammatory activities from Solanum violaceum.
AID423018Antiinflammatory activity against human neutrophils assessed as inhibition of fMLP/CB-induced elastase release2009Journal of natural products, Jan, Volume: 72, Issue:1
Amides and benzenoids from Zanthoxylum ailanthoides with inhibitory activity on superoxide generation and elastase release by neutrophils.
AID1768550Inhibition of GlpG in Escherichia coli BL21 assessed as inhibition of FP-Rh labeling at 200 uM treated with compound prior to FP-Rh addition by competitive ABPP based analysis2021Bioorganic & medicinal chemistry letters, 10-01, Volume: 49Development of succinimide-based inhibitors for the mitochondrial rhomboid protease PARL.
AID538217Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Ixorapeptide I and ixorapeptide II, bioactive peptides isolated from Ixora coccinea.
AID593488Inhibition of chymotrypsin assessed as p-nitroaniline release at 20 uM measured at every 6 mins for 15 mins using Bz-L-Tyr-pNA as a substrate2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Synthesis and biological evaluation of novel irreversible serine protease inhibitors using amino acid based sulfonyl fluorides as an electrophilic trap.
AID1768549Inhibition of FLAG-tagged human PARL transfected in HEK293T cell membrane assessed as inhibition of FP-Rh labeling at 200 uM treated with compound prior to FP-Rh addition by competitive ABPP based analysis2021Bioorganic & medicinal chemistry letters, 10-01, Volume: 49Development of succinimide-based inhibitors for the mitochondrial rhomboid protease PARL.
AID480908Toxicity in african green monkey Vero cells by alamar blue assay2010Journal of natural products, May-28, Volume: 73, Issue:5
Action of a pentacyclic triterpenoid, maslinic acid, against Toxoplasma gondii.
AID328636Antiinflammatory activity in human neutrophils assessed as inhibition of formyl-L-methionyl-L-leucyl-L-phenylalanine/cytochalasin B-induced elastase release2008Journal of natural products, Feb, Volume: 71, Issue:2
Neolignans, a coumarinolignan, lignan derivatives, and a chromene: anti-inflammatory constituents from Zanthoxylum avicennae.
AID420675Antiinflammatory activity in fMLP/cytochalasin B-stimulated human neutrophils assessed as inhibition of elastase release after 5 mins2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Design and synthesis of new N-(fluorenyl-9-methoxycarbonyl) (Fmoc)-dipeptides as anti-inflammatory agents.
AID422002Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced elastase release treated 5 mins before fMet-Leu-Phe/Cytochalasin B challenge2009Journal of natural products, Feb-27, Volume: 72, Issue:2
Benzophenone derivatives from the fruits of Garcinia multiflora and their anti-inflammatory activity.
AID703158Inhibition of mouse DAGLalpha expressed in HEK293T cell membrane using [14C]SAG substrate at 10 nM by scintillation counting based radio-TLC assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Assay and inhibition of diacylglycerol lipase activity.
AID593215Inhibition of FMLP/CB-stimulated elastase release in human neutrophils treated for 5 mins before FMLP/CB challenge using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
Inhibitory effects of Mannich bases of heterocyclic chalcones on NO production by activated RAW 264.7 macrophages and superoxide anion generation and elastase release by activated human neutrophils.
AID703169Inhibition of human DAGLalpha expressed in HEK293T cell membrane using [14C]SAG substrate at 10 uM in detergent free solution by scintillation counting based radio-TLC assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Assay and inhibition of diacylglycerol lipase activity.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (945)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990383 (40.53)18.7374
1990's241 (25.50)18.2507
2000's194 (20.53)29.6817
2010's108 (11.43)24.3611
2020's19 (2.01)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.08 (24.57)
Research Supply Index6.90 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index78.19 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (48.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.10%)5.53%
Reviews4 (0.41%)6.00%
Case Studies1 (0.10%)4.05%
Observational0 (0.00%)0.25%
Other980 (99.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]